Impax Pharmaceuticals, the branded products division of Impax
Laboratories, Inc. (NASDAQ: IPXL), today announced that data from the
ASCEND-PD Phase III clinical study involving IPX066 will be presented in
a Platform Presentation at the 64th Annual Meeting of the
American Academy of Neurology in New Orleans, Louisiana, held from April
21 to April 28. IPX066 is an investigational, patented extended release
capsule formulation of carbidopa-levodopa (CD-LD) intended for the
treatment of idiopathic Parkinson's disease. IPX066 is being developed
in collaboration with GlaxoSmithKline (GSK) for territories countries
outside the U.S. and Taiwan.
The presentation information is as follows:
ASCEND-PD Presentation
Title:
Comparison of IPX066, a Novel Investigational Carbidopa-Levodopa (CD-LD)
Extended-Release Formulation, and CD-LD-Entacapone (CLE) in Advanced
Parkinson's Disease (ASCEND-PD Trial)
Date: April 24, 2012
Time: 2:00 p.m.
Location: New Orleans
Ernest N. Memorial Convention Center
Scientific Session: S02
(Treatment of Parkinson's Disease)
Abstract Number: S02.005
UTHealth project aims to improve clinical trials for underserved people with neurological conditions